CuraTeQ Biologics Private Limited, a wholly owned subsidiary of aurobindo pharma , has received approval from ANVISA, the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad. The approval was granted following a successful GMP inspection conducted from May 11 to May 15, 2026. This regulatory endorsement strengthens the company's capability to supply biosimilar products to the Brazilian and broader Latin American markets.

The inspection assessed the facility's compliance for biological API and sterile products. The scope covered four biosimilar products and evaluated the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling facility, and QC testing and release laboratories.

CuraTeQ's drug substance and drug product GMP facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO). The ANVISA approval reaffirms CuraTeQ Biologics' commitment to global regulatory compliance and quality standards.

Inspection Details

The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. B. Adi Reddy, Company Secretary of Aurobindo Pharma Limited, confirmed the development in the filing.

Aurobindo Pharma's wholly owned step-down subsidiary, PT Aurogen Pharma Indonesia, has incorporated a new entity named PT Auro Pharm Indonesia to undertake manufacturing operations in Indonesia. The new subsidiary was incorporated on July 1, 2026, with regulatory approval received on July 9, 2026. The incorporation is part of the company's strategy to expand its manufacturing footprint in the pharmaceutical sector.

The disclosure regarding this incorporation was made to the National Stock Exchange of India Limited and BSE Limited on July 10, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that PT Auro Pharm Indonesia is a wholly owned step-down subsidiary and falls under the definition of a related party transaction. The promoters and promoter group of Aurobindo Pharma have no interest in this transaction.

The initial subscription to the share capital of PT Auro Pharm Indonesia was made entirely in cash. The total capital subscribed amounts to IDR 20,000,000,000, divided into 2000 equity shares with a face value of IDR 10,000,000 each. Aurobindo Pharma holds 100% of the shareholding and control in the newly incorporated entity.

Key Details of PT Auro Pharm Indonesia

No specific governmental or regulatory approvals were required for this acquisition beyond the standard incorporation process. As a newly formed entity, PT Auro Pharm Indonesia does not have a historical turnover record for the past three years. The primary object of the subsidiary is to engage in manufacturing operations, aligning with Aurobindo Pharma's core business activities.